Enterprise Value
-19.78M
Cash
37.27M
Avg Qtr Burn
-7.213M
Short % of Float
0.07%
Insider Ownership
2.82%
Institutional Own.
10.17%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WP1220 Details Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma | Phase 2 Update | |
WP1066 (p-STAT3 inhibitor) Details Cancer, Brain tumor, Solid tumor/s, Glioma | Phase 2 Initiation | |
Annamycin + Ara-C Details Blood cancer, Cancer, Acute myeloid leukemia | Phase 1/2 Data readout | |
WP1066 (p-STAT3 inhibitor) Details Brain tumor, Solid tumor/s, Glioblastoma, Cancer | Phase 1/2 Data readout | |
Annamycin Details Soft tissue sarcoma, Solid tumor/s, Cancer, Lung Metastases, Sarcoma | Phase 1/2 Data readout | |
WP1122 Details COVID-19 | Phase 1b Update |